Ali Eman, Owais Rabia, Sheikh Ayesha, Shaikh Asim
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Ann Med Surg (Lond). 2022 Jul 13;80:104157. doi: 10.1016/j.amsu.2022.104157. eCollection 2022 Aug.
Olumniant (Barcitinib) has gained swift approval by the Food and Drug Administration (FDA) as a promising medication for the treatment of adults with severe Alopecia Areata. This drug has proven to be effective for various conditions including Covid-19 and Rheumatoid Arthritis as well as being found to be less costly and minimally invasive, with no need for post-operative management. However, its use has some considerable potential implications before its prescription can be made commonplace. Therefore, more trials need to be conducted to establish a more rigid safety profile.
欧鲁明（巴瑞替尼）已迅速获得美国食品药品监督管理局（FDA）的批准，成为一种有前景的药物，用于治疗重度斑秃的成年人。这种药物已被证明对包括新冠病毒病和类风湿性关节炎在内的各种病症有效，而且成本较低、侵入性极小，无需术后管理。然而，在其处方变得普遍之前，其使用存在一些相当大的潜在影响。因此，需要进行更多试验以建立更严格的安全档案。
